From: Dental implant bioactive surface modifications and their effects on osseointegration: a review
Author | Animal – bone site | Mode of surface modification | Length of study | Findings |
---|---|---|---|---|
Becker et al. [24] | Dog – mandible and tibia | 1. C: sand-blasted and acid-etched 2. CSA 3. BMP-A: non-covalently immobilized rhBMP-2 (596 ng/cm2) 4. BMP-B: covalently immobilized rhBMP-2 (819 ng/cm2) | 4 weeks | BIC and BD: BMP-B > BMP-A > CSA > C |
Lan et al. [25] | Rabbit - femur | 1. A: with rhBMP-2 2. B: without rhBMP-2 | 12 weeks | - Pull-out strength: A (36.5 N) > B (27.6 N) - Bone formation: A > B |
Liu et al. [26] | Pig – maxilla | 1. Ti + CaP + BMP-2 inc 2. Ti + CaP + BMP-2 ads 3. Ti + CaP + BMP-2 ads + inc 4. Ti + CaP 5. Ti + BMP-2 ads 6. Ti | 3 weeks | - Bone volume was highest for Ti & CaP and lowest for CaP/BMP-2 ads - Bone-interface coverage of the implant surface was highest for CaP and lowest for Ti/BMP-2 ads |
Wikesjo et al. [27] | Dog - mandible | 1. TPO + rhBMP-2 (0.2 mg/ml) ads 2. TPO + rhBMP-2 (4.0 mg/ml) ads 3. TPO (control) | 8 weeks | % of BIC: - TPO surfaces coated with 0.2 mg/ml rhBMP-2: 43.3% vs. TPO control: 71.7% - TPO surfaces coated with 4 mg/ml rhBMP-2: 35.4% vs. TPO control: 68.2% |
Wikesjo et al. [28] | Monkey - maxilla | 1. TPO + rhBMP-2 (2.0 mg/ml) ads 2. TPO + rhBMP-2 (0.2 mg/ml) ads 3. TPO (control) | 16 weeks | % of BIC - Uncoated TPO surfaces: 74 - 75% - TPO surfaces coated with 2.0 mg/ml rhBMP-2: 43% - TPO surfaces coated with 0.2 mg/ml rhBMP-2: 37% |
Huh et al. [29] | Dog - mandible | 1. rhBMP-2 coated implants 2. uncoated anodized implants (control) | 8 weeks | % of BIC - Uncoated control: 40.16% - rhBMP-2 coated: 41.88% Implant stability test - Uncoated control: ISQ = 74.27 - rhBMP-2 coated: ISQ = 79.21 |
Hunziker et al. [30] | Pig - maxilla | 1. Ti 2. Ti + CaP 3. Ti + rhBMP-2 (10 μg) ads 4. Ti + CaP + rh BMP-2 (10 μg) ads 5. Ti + CaP + rh BMP-2 (12.95 μg) inc 6. Ti + CaP + rhBMP-2 ads + inc | 1, 2, and 3 weeks | Volume fraction of total bone - Ti + CaP + BMP-2, with either ads or inc or both, have the highest values at 1 week - Ti + CaP + BMP-2 inc and Cap groups have the highest values at 2 weeks - Ti + CaP + BMP-2 inc and Cap groups have the highest values at 3 weeks |
Kim et al. [31] | Dog - mandible | 1. SLA (control) 2. SLA + rhBMP-2 (0.1 mg/mL) 3. SLA + rhBMP-2 (0.5 mg/mL) 4. SLA + rhBMP-2 (1 mg/mL) | 8 weeks | % of BIC - Control: Buccal: 0.67%; Lingual: 23.37% - rhBMP-2 (0.1 mg/mL): Buccal: 10.24%; Lingual: 26.50% - rhBMP-2 (0.5 mg/mL): Buccal: 24.47%; Lingual: 35.45% - rhBMP-2 (1 mg/mL): Buccal: 18.42%; Lingual: 33.43% BV - Control: Buccal: 2.77%; Lingual: 46.50% - rhBMP-2 (0.1 mg/mL): Buccal: 13.30%; Lingual: 60.50% - rhBMP-2 (0.5 mg/mL): Buccal: 33.67%; Lingual: 66.17% - rhBMP-2 (1 mg/mL): Buccal: 35.67%; Lingual: 65.00% Implant stability test - Control: ISQ = 60.17 - rhBMP-2 (0.1 mg/mL): ISQ = 64.83 - rhBMP-2 (0.5 mg/mL): ISQ = 71.67 - rhBMP-2 (1 mg/mL): ISQ = 72.00 |